Unum Therapeutics Strengthens and Expands Leadership Team
13 juin 2019 18h06 HE
|
Unum Therapeutics Inc.
– Matthew Osborne Appointed as Chief Financial Officer –– Jessica Sachs Promoted to Chief Medical Officer –– Mert Aktar Appointed as Head of Business and Corporate Development – CAMBRIDGE, Mass.,...
Unum Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update
13 mai 2019 07h00 HE
|
Unum Therapeutics Inc.
- Advancing ACTR Clinical Programs in Non-Hodgkin Lymphoma, Multiple Myeloma, and HER2+ Advanced Cancers Through Dose Escalation Studies with Data Expected from All Four Ongoing Trials in Second Half...
Unum Therapeutics to Host First Quarter 2019 Financial Results Conference Call and Webcast on May 13, 2019 at 8:00 A.M. ET
06 mai 2019 07h00 HE
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., May 06, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat...
Unum Therapeutics to Present at Two Upcoming Investor Conferences
02 avr. 2019 07h00 HE
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat...
Unum Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
28 mars 2019 07h00 HE
|
Unum Therapeutics Inc.
- Advancing ATTCK-20-03 Phase 1 Trial in CD20+ Non-Hodgkin Lymphoma Toward Expansion Phase; Completing ATTCK-20-2 Study - - Continued Dose Escalation of ATTCK-17-01 Trial in Multiple Myeloma - -...
Unum Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast on March 28, 2019 at 8:00 A.M. ET
21 mars 2019 07h00 HE
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat...
Unum Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference 2019
05 mars 2019 07h00 HE
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat...
CORRECTING and REPLACING -- Unum Therapeutics Announces 2019 Goals and Expected Milestones
04 janv. 2019 18h15 HE
|
Unum Therapeutics Inc.
In a release issued yesterday under the same headline by Unum Therapeutics Inc. (NASDAQ: UMRX), please note the anticipated 2019 milestone for BOXR1030 has been changed from initiating clinical...
Unum Therapeutics Announces 2019 Goals and Expected Milestones
03 janv. 2019 07h00 HE
|
Unum Therapeutics Inc.
- Multiple Data Readouts from ATTCK-20-03 and ATTCK-17-01 Expected in 2019 - - Initial Data on ATTCK-34-01, Unum’s First Program in Solid Tumors, Expected in Second Half of 2019 - - First...
Unum Therapeutics Announces Transition of Chief Financial Officer
03 janv. 2019 07h00 HE
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of novel cellular immunotherapies,...